Opinion|Videos|September 16, 2024
Challenges in Managing Co-Morbid CRM Conditions
Key Takeaways
- Polypharmacy and drug-drug interactions complicate the management of co-morbid CRM conditions, necessitating careful medication review and adjustment.
- Overlapping symptoms of CRM conditions require a multidisciplinary approach for accurate diagnosis and effective management.
A panel of medical experts examines the challenges in managing co-morbid cardiometabolic conditions, emphasizing the most prevalent complications associated with this disease state.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the major clinical challenges in managing patients with co-morbid CRM conditions?
This activity is supported by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company who provided financial support for this program.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Adam Kittai, MD, on Sequencing, Cost, and the Road to CLL Cure
2
COVID-19 May Follow a Different Seasonal Pattern Than Influenza, RSV
3
Real-World Data Show MASH Progresses Faster Than Trials Suggest
4
Sarcoma's Rarity Limits Trials and Biomarker-Driven Treatment Options: Alexander Spira, MD, PhD, FACP, FASCO
5